Acute promyelocytic leukemia current treatment algorithms.
Yilmaz M, Kantarjian H, Ravandi F.
Blood Cancer J. 2021 Jun 30;11(6):123. doi: 10.1038/s41408-021-00514-3.
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti CA, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller PJ, Dörr J, Seifert M, Cadilha BL, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner C, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S.
Nat Biotechnol. 2023 Nov;41(11):1618-1632. doi: 10.1038/s41587-023-01684-0. Epub 2023 Mar 13.
Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies.
Zehtabcheh S, Soleimani Samarkhazan H, Asadi M, Zabihi M, Parkhideh S, Mohammadi MH.
Biomark Res. 2025 May 13;13(1):73. doi: 10.1186/s40364-025-00786-y.
[Acute myeloid Leukemia].
Braess J.
Dtsch Med Wochenschr. 2016 Nov;141(24):1748-1751. doi: 10.1055/s-0042-112505. Epub 2016 Nov 11.
Immunophenotypic pattern of myeloid populations by flow cytometry analysis.
Gorczyca W, Sun ZY, Cronin W, Li X, Mau S, Tugulea S.
Methods Cell Biol. 2011;103:221-66. doi: 10.1016/B978-0-12-385493-3.00010-3.
Anti-TIM3 chimeric antigen receptor-natural killer cells preferentially target primitive acute myeloid leukemia cells with minimal fratricide and exhaustion.
Klaihmon P, Samart P, Rojanasakul Y, Issaragrisil S, Luanpitpong S.
Exp Hematol Oncol. 2024 Jul 11;13(1):67. doi: 10.1186/s40164-024-00534-2.
Multiparameter flow cytometry in the diagnosis and management of acute leukemia.
Peters JM, Ansari MQ.
Arch Pathol Lab Med. 2011 Jan;135(1):44-54. doi: 10.5858/2010-0387-RAR.1.
Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding.
Sakamoto K, Takeuchi K.
J Clin Exp Hematop. 2025;65(1):1-16. doi: 10.3960/jslrt.24069.
SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia.
Gabellier L, De Toledo M, Chakraborty M, Akl D, Hallal R, Aqrouq M, Buonocore G, Recasens-Zorzo C, Cartron G, Delort A, Piechaczyk M, Tempé D, Bossis G.
Haematologica. 2024 Jan 1;109(1):98-114. doi: 10.3324/haematol.2023.282704.
Essential thrombocythemia terminating in acute leukemia with minimal myeloid differentiation--a brief review of recent literature.
Shibata K, Shimamoto Y, Suga K, Sano M, Matsuzaki M, Yamaguchi M.
Acta Haematol. 1994;91(2):84-8. doi: 10.1159/000204260.
